Influence of latanoprost on the corneal epithelial barrier function in glaucoma patients

Ophthalmologica

Volumn 216, Issue 5, 2002, Pages 351-354

  Ishibashi, Takeshi ^a   Yokoi, Norihiko ^a   Ohtsuki, Masanori ^a   Mori, Kazuhiko ^a   Komuro, Aoi ^a   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Beta blocker; Corneal epithelial barrier function; Fluorophotometry; Isopropyl unoprostone; Latanoprost

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPIVEFRINE; FLUORESCEIN; LATANOPROST; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; CONTRAST MEDIUM; PROSTAGLANDIN F;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG EFFICACY; FLUOROPHOTOMETRY; GLAUCOMA; HUMAN; MONOTHERAPY; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; INTRAOCULAR PRESSURE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERMEABILITY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DRUG THERAPY, COMBINATION; EPITHELIUM, CORNEAL; FLUORESCEIN; FLUOROPHOTOMETRY; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; PERMEABILITY; PROSTAGLANDINS F, SYNTHETIC;

EID: 0036717548     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066180     Document Type: Article

References (25)

1. Alm A, Widengard I: Latanoprost: Experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78:71-76.
2. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araic M: A comparison of latanoprost and timolol in primary open-angle glaucoma and occular hypertension: A 12-week study. Arch Ophthalmol 1996;114:929-932.
3. Camras CB, Wax MB, Ritch R, Weinreb R, Robin AL, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minekler D, Zimmerman T, Stjernschantz J: Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol 1998;126:390-399.
4. Alm A, Widengard I, Kjellgren D, Söderström M, Fristöm B, Heijl A, Stjernschantz J: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16.
5. Susanna R Jr, Nicolela MT, Oga E: Additive effect of latanoprost ot the combination of timolol and dorzolamide. J Glaucoma 2000;9:183-186.
6. Fristrom B, Nilsson SE: Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-665.
7. Shin DH, McCracken MS, Bendel RE, Pearlman R, Juzych MS, Hughes BA, Schulz LL, Kim C, Back NH: The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology 1999;106:386-390.
8. Eisenberg DL, Camras CB: A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Drug Saf 1999;20:505-514.
9. Suzuki M, Mishima HK, Masuda K, Araie M, Kitazawa Y, Azuma I: Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan. Jpn J Ophthalmol 2000;44:33-38.
10. Watson PG: Latanoprost: Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998;105:82-87.
11. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S: Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999;117:34-40.
12. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R: Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.
13. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC: Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77:668-672.
14. Wand M, Gilbert CM, Liesegang TJ: Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-604.
15. Kaufman HE, Varnell ED, Thompson HW: Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-536.
16. Sudesh S, Cohen EJ, Rapuano CJ, Wilson RP: Corneal toxicity associated with latanoprost. Arch Opthalmol 1999;117:539-540.
17. Komuro A, Yokoi N, Kinoshita S: Corneal epithelial disturbance during topical use of latanoprost. Nippon Ganka Gakkai Zasshi 2000;104:737-739.
18. 2α ophthalmic solution. Rinsho Ganka 1995;49:1845-1848.
19. Yokoi N, Kinoshita S: Clinical evaluation of corneal epithelial barrier function with the slit-lamp fluorophotometer. Cornea 1995;14:485-489.
20. Ishibashi T, Mori K, Adachi W, Naruse S, Hino Y, Komuro A, Yokoi N, Kinoshita S: Effect of latanoprost on the barrier function of corneal epithelium. Nippon Ganka Gakkai Zasshi 2001;105:333-337.
21. 2α on the barrier function of corneal epithelium. Rinsho Ganka 1996;50:1109-1111.
22. Komuro A, Yokoi N, Matsumoto Y, Kinoshita S: Effectiveness of isopropyl unoprostone on corneal epithelial barrier function. Atarashii Ganka 1996;13:442-444.
23. 2α isopropyl unoprostone. Nippon Ganka Gakkai Zasshi 1998;102:101-105.
24. Thygesen J, Aaen K, Theodorsen F, Kessing SV, Prause JU: Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000;78:37-44.
25. Niiya A, Yokoi N, Matsumoto Y, Komuro A, Ishibashi T, Tomii S, He J, Kinoshita S: Effect of beta-blocker eyedrops on corneal epithelial barrier function. Ophthalmologica 2000;214:332-336.